Allspring Global Investments Holdings LLC Sells 580 Shares of DaVita Inc. (NYSE:DVA)

Allspring Global Investments Holdings LLC cut its holdings in DaVita Inc. (NYSE:DVA) by 21.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,129 shares of the company’s stock after selling 580 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in DaVita were worth $349,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of DVA. Sumitomo Mitsui Trust Holdings Inc. grew its stake in shares of DaVita by 1.6% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 134,823 shares of the company’s stock worth $18,612,000 after purchasing an additional 2,129 shares during the last quarter. First Trust Direct Indexing L.P. grew its stake in shares of DaVita by 3.9% in the first quarter. First Trust Direct Indexing L.P. now owns 2,590 shares of the company’s stock worth $358,000 after purchasing an additional 98 shares during the last quarter. Janney Montgomery Scott LLC grew its stake in shares of DaVita by 175.5% in the first quarter. Janney Montgomery Scott LLC now owns 18,937 shares of the company’s stock worth $2,614,000 after purchasing an additional 12,064 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. grew its stake in shares of DaVita by 11.9% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,377 shares of the company’s stock worth $328,000 after purchasing an additional 253 shares during the last quarter. Finally, Quent Capital LLC grew its stake in shares of DaVita by 21.0% in the first quarter. Quent Capital LLC now owns 581 shares of the company’s stock worth $80,000 after purchasing an additional 101 shares during the last quarter. 90.12% of the stock is owned by institutional investors.

DaVita Price Performance

DVA stock opened at $141.59 on Friday. The firm has a 50 day moving average price of $157.71 and a 200-day moving average price of $146.05. DaVita Inc. has a 52-week low of $76.64 and a 52-week high of $168.50. The firm has a market capitalization of $11.61 billion, a price-to-earnings ratio of 15.27, a PEG ratio of 0.79 and a beta of 0.89. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.12 and a current ratio of 1.37.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. During the same quarter in the previous year, the business posted $2.85 earnings per share. DaVita’s revenue for the quarter was up 4.6% on a year-over-year basis. Equities research analysts forecast that DaVita Inc. will post 9.73 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Javier Rodriguez sold 32,176 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $155.93, for a total value of $5,017,203.68. Following the completion of the transaction, the chief executive officer now directly owns 905,659 shares in the company, valued at $141,219,407.87. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Javier Rodriguez sold 32,176 shares of DaVita stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the completion of the sale, the chief executive officer now directly owns 905,659 shares of the company’s stock, valued at approximately $141,219,407.87. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 173,482 shares of company stock worth $27,387,069 in the last three months. Insiders own 2.00% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on the stock. Bank of America raised their price objective on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. UBS Group raised their price objective on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Truist Financial raised their price objective on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Barclays raised their price objective on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday. Finally, TD Cowen raised their price objective on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.